Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436160 · ClinicalTrials.gov registry record · Early Phase 1
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
A Early Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT03436160: Completed Early Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT03436160 is a Early Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03436160, a Early Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Open-label, randomized, microdose study
Primary Outcome
Pharmacokinetic parameters of the 3 compounds will be calculated from the plasma-time data and descriptive statistics assessed . No statistical significance inferences will be made.
Interventions
- DRUG WR826647
- DRUG WR909388
- DRUG WR909390
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2018-11-03 |
| Phase | Early Phase 1 |
What the finished NCT03436160 record still lists
NCT03436160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 3 interventions - of which WR826647 is the first listed.
NCT03436160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03436160 about?
NCT03436160 is a clinical study titled "Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds". Open-label, randomized, microdose study
What is the current status of trial NCT03436160?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2018-08-10. Estimated completion is 2018-11-03.
What interventions are being tested in trial NCT03436160?
The interventions under investigation include: WR826647 (DRUG), WR909388 (DRUG), WR909390 (DRUG).
Who is sponsoring clinical trial NCT03436160?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03436160's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI